Your browser doesn't support javascript.
loading
European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.
Vermunt, Lisa; Veal, Colin D; Ter Meulen, Lea; Chrysostomou, Charalambos; van der Flier, Wiesje; Frisoni, Giovanni B; Guessous, Idris; Kivipelto, Miia; Marizzoni, Moira; Martinez-Lage, Pablo; Molinuevo, José Luis; Porteous, David; Ritchie, Karen; Scheltens, Philip; Ousset, Pierre-Jean; Ritchie, Craig W; Luscan, Gerald; Brookes, Anthony J; Visser, Pieter Jelle.
Afiliação
  • Vermunt L; Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: L.Vermunt@vumc.nl.
  • Veal CD; Department of Genetics, University of Leicester, Leicester, UK.
  • Ter Meulen L; Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.
  • Chrysostomou C; Department of Genetics, University of Leicester, Leicester, UK.
  • van der Flier W; Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.
  • Frisoni GB; Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.
  • Guessous I; Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland; Unit of Population Epidemiology, Division of Primary Care Medicine, Department of Community Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland; Depar
  • Kivipelto M; National Institute for Health and Welfare, Helsinki, Finland; Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden; University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
  • Marizzoni M; Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Martinez-Lage P; Neurología, Fundación CITA-Alzhéimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, Guipúzcoa, Spain.
  • Molinuevo JL; BarcelonaBeta Brain Research Center, Fundacio Pasqual Maragall, Universitat Pompeu Fabra, Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.
  • Porteous D; Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Ritchie K; Institut National de la Sante et de la Recherche Medicale, U1061 Neuropsychiatrie, Montpellier, France; University of Montpellier, Montpellier, France; Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
  • Scheltens P; Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.
  • Ousset PJ; Department of Geriatric Medicine, CHU Toulouse, Gerontopole and INSERM UMR 1027, Toulouse, France.
  • Ritchie CW; Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK.
  • Luscan G; Global Innovative Pharma Business - Clinical Sciences, Pfizer, Paris, France.
  • Brookes AJ; Department of Genetics, University of Leicester, Leicester, UK.
  • Visser PJ; Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands.
Alzheimers Dement ; 14(6): 837-842, 2018 06.
Article em En | MEDLINE | ID: mdl-29604264
INTRODUCTION: It is a challenge to find participants for Alzheimer's disease (AD) prevention trials within a short period of time. The European Prevention of Alzheimer's Dementia Registry (EPAD) aims to facilitate recruitment by preselecting subjects from ongoing cohort studies. This article introduces this novel approach. METHODS: A virtual registry, with access to risk factors and biomarkers for AD through minimal data sets of ongoing cohort studies, was set up. RESULTS: To date, ten cohorts have been included in the EPAD. Around 2500 participants have been selected, using variables associated with the risk for AD. Of these, 15% were already recruited in the EPAD longitudinal cohort study, which serves as a trial readiness cohort. DISCUSSION: This study demonstrates that a virtual registry can be used for the preselection of participants for AD studies.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema de Registros / Ensaios Clínicos como Assunto / Seleção de Pacientes / Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema de Registros / Ensaios Clínicos como Assunto / Seleção de Pacientes / Doença de Alzheimer Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article